Research Paper Volume 16, Issue 11 pp 10108—10131

Figure 9. Drug sensitivity analyses among high- and low-risk categories. (A) Estimated IC₅₀ of bleomycin in the elevated-risk category were lower than in the decreased-risk category. (B) Estimated IC₅₀ of bosutinib in the elevated-risk category were higher than in the decreased-risk category. (C) Estimated IC₅₀ of cisplatin in the elevated-risk category were lower than in the decreased-risk category. (D, E, F) Estimated IC₅₀ of cyclopamine, dasatinib and docetaxel in the elevated-risk category were higher than in the decreased-risk category. (G) Estimated IC₅₀ of gemcitabine in the elevated-risk category were lower than in the decreased-risk category. (H, I) Estimated IC₅₀ of metformin and methotrexate in the elevated-risk category were higher than in the decreased-risk category. (J, K) Estimated IC₅₀ of mitomycin C and paclitaxel in the elevated-risk category were lower than in the decreased-risk category. (L) Estimated IC₅₀ of rapamycin in the elevated-risk category were higher than in the decreased-risk category.